IceCure Medical announces publication of study on cryoablation

IceCure Medical announced the publication of an independent study titled “Acceptance and results of cryoablation for the treatment of early breast cancer in non-surgical patients” in the British Journal of Radiology, a publication of the British Institute of Radiology. The single-site study, led by Lucia L. Garna Lopez, was conducted by researchers in the radiology, oncology, and surgery departments at Hospital Lucus Augusti in Lugo, Spain. The aim of the study was to evaluate the acceptance of percutaneous cryoablation treatment by patients with early-stage breast cancer who choose not to have surgery. Of the 45 patients offered cryoablation with ProSense, 43 patients, or 95.6% accepted. 36 of these, representing 39 malignant tumors, proceeded to undergo cryoablation. The median age of patients treated with cryoablation was 87, with a range of 60-96. After a median follow-up of 16 months, the complete ablation rate in luminal breast cancer with tumors less than or equal to 25mm was 100%. No major complications were seen.